tiprankstipranks
Aspen Pharmacare Holdings Limited (DE:LDZA)
FRANKFURT:LDZA

Aspen Pharmacare Holdings (LDZA) Price & Analysis

0 Followers

LDZA Stock Chart & Stats

€6.75
-€0.05(-0.57%)
At close: 4:00 PM EST
€6.75
-€0.05(-0.57%)

LDZA FAQ

What was Aspen Pharmacare Holdings Limited’s price range in the past 12 months?
Aspen Pharmacare Holdings Limited lowest stock price was €4.50 and its highest was €7.75 in the past 12 months.
    What is Aspen Pharmacare Holdings Limited’s market cap?
    Aspen Pharmacare Holdings Limited’s market cap is €3.48B.
      When is Aspen Pharmacare Holdings Limited’s upcoming earnings report date?
      Aspen Pharmacare Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 79 days.
        How were Aspen Pharmacare Holdings Limited’s earnings last quarter?
        Aspen Pharmacare Holdings Limited released its earnings results on Mar 03, 2026. The company reported €0.164 earnings per share for the quarter, beating the consensus estimate of N/A by €0.164.
          Is Aspen Pharmacare Holdings Limited overvalued?
          According to Wall Street analysts Aspen Pharmacare Holdings Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Aspen Pharmacare Holdings Limited pay dividends?
            Aspen Pharmacare Holdings Limited does not currently pay dividends.
            What is Aspen Pharmacare Holdings Limited’s EPS estimate?
            Aspen Pharmacare Holdings Limited’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Aspen Pharmacare Holdings Limited have?
            Aspen Pharmacare Holdings Limited has 446,252,320 shares outstanding.
              What happened to Aspen Pharmacare Holdings Limited’s price movement after its last earnings report?
              Aspen Pharmacare Holdings Limited reported an EPS of €0.164 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Aspen Pharmacare Holdings Limited?
                Currently, no hedge funds are holding shares in DE:LDZA
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Aspen Pharmacare Holdings Limited

                  Operating worldwide, Aspen Pharmacare Holdings Limited, together with its subsidiaries, focuses on the development, production, and global distribution of specialized and branded pharmaceutical products. The company's business activities are structured into two main divisions: Commercial Pharmaceuticals and Manufacturing. Under its Anaesthetics portfolio, Aspen offers diverse products such as general anesthetics, muscle relaxants, and topical agents. Its Thrombosis brand is dedicated to a variety of injectable anticoagulants, with an emphasis on low molecular weight heparins, Xa inhibitors, and heparin derivatives. Additionally, Aspen provides a range of branded consumer, prescription, and over-the-counter medications through regional brands. These include Circadin (for sleep management), Foxair (for respiratory conditions), Maltofer (an iron supplement), Mybulen (a painkiller), and Zyloric (which controls uric acid production). Beyond its proprietary offerings, the company also manufactures and supplies active pharmaceutical ingredients (APIs) and finished dosage form products to external clients. Founded in 1850, Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa.

                  Aspen Pharmacare Holdings (LDZA) Earnings & Revenues

                  LDZA Company Deck

                  LDZA Earnings Call

                  Q2 2026
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The call conveyed a cautiously optimistic outlook: commercial pharmaceutical operations are performing well with solid revenue and margin expansion, GLP-1 products are delivering rapid market momentum, and the group has materially improved cash generation. Major near-term headwinds stem from a significant manufacturing contract loss and continuing sterile business losses, which depressed H1 EBITDA and HEPS. The planned APAC divestment (expected net proceeds >ZAR 25 billion) and ongoing cost and reshaping actions are positioned to materially reduce debt, unlock value, and fund a recovery—management expects a much stronger second half and recovery to FY27 levels. Overall, positives (strong cash flow, commercial pharma/GLP-1 growth, APAC monetization) outweigh the near-term negatives (manufacturing/steriles impact and H1 earnings decline), supporting a constructive outlook.View all DE:LDZA earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Aspen Pharmacare Holdings
                  Bristol-Myers Squibb
                  Dr Reddy's Laboratories
                  Pfizer
                  Bausch Health Companies
                  Sanofi
                  Teva Pharmaceutical
                  Popular Stocks